Share This Page
Drugs in ATC Class D05B
✉ Email this page to a colleague
Subclasses in ATC: D05B - ANTIPSORIATICS FOR SYSTEMIC USE
Market Dynamics and Patent Landscape for ATC Class D05B – Antipsoriatics for Systemic Use
Summary
The ATC (Anatomical Therapeutic Chemical) classification D05B pertains to systemic antipsoriatic agents, primarily including biologics and systemic immunosuppressants used in moderate to severe psoriasis management. The psoriasis therapeutics market is characterized by rapid innovation, expanding biologic pipelines, and evolving patent landscapes driven by advancements in monoclonal antibodies, small molecule inhibitors, and biosimilars.
Market dynamics reveal a blend of high unmet needs, patent expirations, and a shift toward personalized medicine. Patent landscapes are complex, with key patents covering novel biologics, formulations, delivery methods, and combination therapies. The industry faces challenges from patent cliffs, generic and biosimilar entry, and regulatory shifts, which impact overall market growth.
This report synthesizes current market trends, patent strategies, and competitive dynamics within D05B, providing actionable insights for stakeholders.
What Are the Key Market Drivers and Constraints in the D05B Class?
| Drivers | Implications | Constraints | Implications |
|---|---|---|---|
| Rising Prevalence of Psoriasis | Projected CAGR of 7.3% (2022-2028)[1] | Patent Expirations | Loss of exclusivity for key biologics impacts revenue |
| Advances in Biologic Therapies | Increased efficacy & safety profile | High Development Costs | R&D investments exceed $1bn per pipeline candidate |
| Shift Toward Personalized Medicine | Biomarkers guide therapy choice | Strict Regulatory Environment | Approval delays & increased compliance costs |
| Patient Demand for Safer, Less Frequent Dosing | Favor biologics with longer half-life | Pricing Pressures & Reimbursement Uncertainty | Impact on profit margins |
| Technological Innovations (e.g., Biosimilars, Small Molecules) | Market competition intensifies | Patent Litigation & Strategies | Patent disputes may delay market entry |
What Does the Current Patent Landscape Look Like for D05B Agents?
Patent Filing Trends (2010–2023)
| Year | Number of Patent Submissions | Key Patent Holders | Notable Patents | Focus Areas | |--------|----------------------------|----------------/--------------|----------------|--------------| | 2010–2014 | ~1500 | Novartis, Amgen, Johnson & Johnson | First patents for biologics like ustekinumab (Stelara) | Monoclonal antibodies targeting IL-12/23 | | 2015–2019 | ~2000 | Dermatology-focused biotech firms | Patents on biosimilar formulations and delivery methods | Biosimilar process patents, novel formulations | | 2020–2023 | ~2500 | Biotech startups, established pharma | Patents for JAK inhibitors, personalized delivery systems | Small molecules, JAK pathway inhibitors |
Major Patent Holders
| Company | Key Patents | Focus Area | Patent Expiry Goals | Notes |
|---|---|---|---|---|
| AbbVie | Humira biosimilar patents | Anti-TNF biologics | 2034 | Patent challenges ongoing |
| Novartis | Ustekinumab (Stelara) | IL-12/23 inhibitors | 2028 | Biosimilar filings increasing |
| Amgen | Tildrakizumab | IL-23 inhibitors | 2029 | Biosimilar competition anticipated |
| Janssen | Guselkumab | IL-23 inhibitor | 2029 | Patent life extended through formulations |
| Eli Lilly | JAK inhibitors (e.g., Baricitinib) | Small molecules | 2032 | Patent families cover method of use & composition |
Patent Strategies
- Polyphasic Patents: Cover combinations of biologics and small molecules.
- Formulation Patents: Extend exclusivity with novel delivery mechanisms.
- Method-of-Use Patents: Protect specific indications or dosing regimens.
- Biosimilar & Interchangeability Patents: Focused on regulatory pathway advantages.
How Do Market Players Position Themselves in the D05B Patent Landscape?
Innovator Companies
- Focus on new biologic targets, such as JAK-STAT pathway inhibitors and IL-17 blockers.
- Use patent thickets to delay biosimilar entry.
- Exploit composite patents for combination therapies.
Generic and Biosimilar Manufacturers
- Target expiring biologic patents.
- File biosimilar applications post patent expiry; some pursue patent challenge strategies.
- Engage in litigation and settlements to delay biosimilar market entry.
Emerging Biotechs
- Innovate with small molecule alternatives showing shorter development timelines.
- Focus on biosimilars, especially for blockbuster agents nearing patent expiry.
- Strategic collaborations with big pharma to access pipeline assets.
What Are the Key Market Trends?
| Trend | Description | Impact |
|---|---|---|
| Biosimilar Competition | Growth in biosimilar filings, e.g., Sandoz and Pfizer entering psoriasis biosimilar space | Price erosion, market segmentation |
| Personalized Therapeutics | Use of biomarkers like genetic and cytokine profiles | Enhanced efficacy, differential patent strategies |
| Digitalization & Delivery Innovations | Long-acting formulations, auto-injectors, and smart delivery systems | Market differentiation, patent extensions |
| JAK Inhibitors & Small Molecules | Oral alternatives gaining regulatory approval | Broadening treatment options, patent challenges |
Comparison of Top Market Players and Their Patent Portfolios
| Company | Key Patents | Focus Areas | Market Strategy | Patent Term & Expiry | Brief Comments |
|---|---|---|---|---|---|
| AbbVie | Humira, Skyrizi | Anti-TNF, IL-23 | Patent litigation, biosimilars | 2034 (Humira), 2033 (Skyrizi) | Leading biologic patent strategy; aggressive defense tactics |
| Novartis | Stelara, Cosentyx | IL-12/23, IL-17 | Diversification with small molecules | 2028 onward | Investing heavily in patent extensions and biosimilars |
| Janssen | Tremfya, Stelara | IL-23, IL-12/23 | Combination therapies & formulations | 2029 | Focused on expanding patent protection via formulation innovations |
| Amgen | Tildrakizumab | IL-23 | Biosimilar pipeline, licensing | 2029 | Active in biosimilar patent challenges |
| Eli Lilly | Olumiant (Baricitinib) | JAK inhibitors | Oral small molecules, method patents | 2032 | Growing pipeline with extensive method-of-use patents |
Regulatory and Policy Impact on Patent Strategies
| Policy / Regulation | Effect on Patent Landscape | Industry Response |
|---|---|---|
| Patent Term Extensions | Extend exclusivity beyond 20 years | Strategic patent filing, supplementary protection certificates |
| Biosimilar Regulations | Accelerate pathway for biosimilar approval | Focus on biosimilar patents, litigation, patent cliffs |
| Data Exclusivity | Protect clinical data for up to 8 years | Delay biosimilar market entry, patent diversification |
| International Patent Harmonization | Simplifies patent prosecution | Expanding global patent filings, regional licensing |
Future Outlook
| Projection | Description | Implications for Stakeholders |
|---|---|---|
| Patent Expiry Waves (2025–2030) | Several blockbuster biologics face patent cliffs | Increased biosimilar activity, price competition |
| Emergence of Next-Generation Biologics | Use of gene editing, PROTACs | New patent filings surpass traditional biologics |
| Combination of Digital & Biologics | Smart delivery, personalized treatment algorithms | New patent frontiers, data-driven IP strategies |
| Global Expansion in Emerging Markets | Growth in Asia-Pacific & Latin America | Diversified patent filings, local patent challenges |
Key Takeaways
- The psoriasis treatment market is evolving rapidly with biologics and small molecules dominating the D05B class, driven by unmet needs and technological innovations.
- Patent landscapes are sophisticated, with key players employing multi-layered patent strategies to extend market exclusivity amidst expiry of blockbuster biologics.
- Patent expirations in the coming decade will catalyze biosimilar entry, intensifying market competition and driving pricing strategies.
- Strategic patent filings exploring formulation, method-of-use, and combination therapies serve as protectors of market share.
- Regulatory policies, such as patent extensions and biosimilar pathways, significantly influence patent strategies and market trajectories.
FAQs
-
What are the dominant biologics in the D05B class, and when do their patents expire?
Major biologics include Humira (AbbVie), Stelara (Johnson & Johnson), Skyrizi (AbbVie), and Cosentyx (Novartis). Patent expiries range from 2028 to 2034, although legal challenges may extend protection. -
How are biosimilars impacting the D05B market landscape?
Biosimilars are eroding revenues for original biologic innovators by offering cost-effective alternatives. Patent expirations open pathways for biosimilar entry, resulting in intensified price competition. -
What role do small molecule therapies, like JAK inhibitors, play in the current market?
Small molecules, including Eli Lilly’s Olumiant, offer oral administration and broader accessibility, supplementing biologics and providing patentable alternatives with different patent strategies. -
What patent strategies are most effective for innovator companies in D05B?
Employing a combination of composition patents, method-of-use claims, formulation patents, and pursuing patent extensions via regulatory pathways remain critical. -
What future trends should industry stakeholders monitor?
Key trends include the rise of next-generation biologics, integration of digital health solutions, evolving biosimilar policies, and expansion into emerging markets.
References
[1] Grand View Research, "Psoriasis Treatment Market Size, Share & Trends Analysis," 2022.
More… ↓
